Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-151.76	-112.03	-100.78	-79.21	-43.76
Depreciation & Amortization	0.26	0.26	0.24	0.21	0
Share-Based Compensation	21.5	23.24	10.05	6.02	1.77
Other Operating Activities	-15.37	-3.99	10.8	2.17	6.36
Operating Cash Flow	-145.37	-92.52	-79.68	-70.8	-35.63
Capital Expenditures	0	0	0	-0.15	0
Change in Investments	-223.62	-63.83	42.28	-9.61	-71.51
Investing Cash Flow	-223.62	-63.83	42.28	-9.76	-71.51
Share Issuance / Repurchase	339.09	246.5	1.12	203.06	95.99
Debt Issued / Paid	15	10	0	0	0
Other Financing Activities	-0.78	-0.86	-0.52	0.05	-
Financing Cash Flow	353.32	255.63	0.6	203.11	95.99
Net Cash Flow	-15.67	99.29	-36.8	122.54	-11.15
Free Cash Flow	-145.37	-92.52	-79.68	-70.95	-35.63
Free Cash Flow Per Share	-2.77	-2.37	-2.29	-2.25	-2.36

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).